| Zanidatamab studied in …STUDIED_INderived29 of 29show fewer |
|---|
| → studied in | NCT05868226Phase 1/Phase 2 · recruiting PRE-ISPY Phase I/II Oncology Platform Program · 29 trials list this drug (20 active) | — | — | Neoplasm,Malignant Neoplasm,Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06324357Phase 1/Phase 2 · recruiting Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread · 29 trials list this drug (20 active) | — | — | Malignant Breast Neoplasm,Esophageal Adenocarcinoma,Gastric Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07841873Phase 2 · not yet recruiting Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors · 29 trials list this drug (20 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04224272Phase 2 · completed Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant · 29 trials list this drug (20 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05152147Phase 3 · active not recruiting A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers · 29 trials list this drug (20 active) | — | — | Gastric Neoplasm,Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06282575Phase 3 · recruiting Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer · 29 trials list this drug (20 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04276493Phase 1/Phase 2 · completed Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab · 29 trials list this drug (20 active) | — | — | Malignant Breast Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07102381Phase 2 · recruiting A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer · 29 trials list this drug (20 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07780968not yet recruiting Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA · 29 trials list this drug (20 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm,HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05035836Phase 2 · recruiting A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) · 29 trials list this drug (20 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06695845Phase 2 · recruiting A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors · 29 trials list this drug (20 active) | — | — | Malignant Breast Neoplasm,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07685704Phase 2 · not yet recruiting Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study · 29 trials list this drug (20 active) | — | — | Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma,HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05027139Phase 1/Phase 2 · completed A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer · 29 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07176312Phase 2 · recruiting Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients · 29 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07631871Phase 2 · not yet recruiting An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy · 29 trials list this drug (20 active) | — | — | Neoplasm,Head and Neck Neoplasm,Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04164199Phase 3 · completed Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies · 29 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05615818Phase 3 · recruiting Personalized Medicine for Advanced Biliary Cancer Patients · 29 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01042379Phase 2 · recruiting I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer · 29 trials list this drug (20 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Early Stage Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07494448Phase 1/Phase 2 · not yet recruiting Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer · 29 trials list this drug (20 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07405476Phase 2 · recruiting Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment · 29 trials list this drug (20 active) | — | — | Colorectal Carcinoma,Malignant Colorectal Neoplasm,Colon Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06435429Phase 3 · recruiting A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer · 29 trials list this drug (20 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07296705Phase 2 · recruiting Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC · 29 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07192068Phase 2 · recruiting Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. · 29 trials list this drug (20 active) | — | — | Sarcoma,Lung Non-Small Cell Carcinoma,Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07243938Phase 2 · not yet recruiting Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) · 29 trials list this drug (20 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm,Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04466891Phase 2 · completed A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers · 29 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03929666Phase 2 · completed A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer · 29 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04578444no longer available An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer · 29 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04513665Phase 2 · completed ZW25 in Women With Endometrial Cancers · 29 trials list this drug (20 active) | — | — | Carcinosarcoma,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02892123Phase 1 · completed Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers · 29 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |